Although preclinical evidence indicates that μ-opioid receptor (MOR) activation might promote tumor progression in hepatocellular carcinoma (Li et al., 2019), the potential survival benefits of an opioid-free anesthetic regime in this context remain speculative and require prospective clinical validation. The gene discussed is OPRM1; the disease is hepatocellular carcinoma.